Literature DB >> 16906132

Loss of heterozygosity at 15q21.3 correlates with occurrence of metastases in head and neck cancer.

Micaela Poetsch1, Britta Kleist.   

Abstract

Deletions on the long arm of chromosome 15 suggesting the presence of potential tumor suppressor genes have been found in several tumors including carcinomas of the colorectum, urinary bladder, breast, lung, and head and neck. Here, we analyzed allelic imbalance on chromosome 15q in head and neck carcinomas and corresponding lymph node metastases to define common regions of aberrations with potential involvement in development and progression of these tumors. We studied a panel of 40 polymorphic microsatellite markers, spanning 15q13-15q26, in 63 head and neck carcinomas and 38 lymph node metastases. Loss of heterozygosity (LOH) could be demonstrated in 34 primary tumors (54%) and 35 metastases (92%). Aberration mapping defined three minimum regions of aberrations: a region between the markers D15S106 and D15S1029 in 15q21.3 (estimated as 3.9 Mb; region 1) was affected in the majority of tumors, whereas two other regions between D15S144 and D15S1040 in 15q13.3-14 (estimated as 2.4 Mb; region 2) and between D15S130 and D15S985 in 15q26.2-26.3 (estimated as 4.7 Mb; region 3) were less often involved. Allelic loss in region 1 correlated with T stages (P=0.0029) and metastatic potential (P=0.0018). LOH in regions 2 and 3 occurred predominantly in metastases (P=0.0129 and P=0.0013, respectively). No correlation with grading, localization, or clinical outcome could be established for any of the affected regions. Our data hint at aberrations in 15q21.3 as a possible important characteristic for head and neck squamous cell carcinomas with risk of progression.

Entities:  

Mesh:

Year:  2006        PMID: 16906132     DOI: 10.1038/modpathol.3800666

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  7 in total

1.  Single nucleotide polymorphism profiling assay to confirm the identity of human tissues.

Authors:  Ronald Huijsmans; Jan Damen; Hans van der Linden; Mirjam Hermans
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

2.  Frequent loss of heterozygosity in the β2-microglobulin region of chromosome 15 in primary human tumors.

Authors:  Isabel Maleno; Natalia Aptsiauri; Teresa Cabrera; Aurelia Gallego; Annette Paschen; Miguel Angel López-Nevot; Federico Garrido
Journal:  Immunogenetics       Date:  2010-11-18       Impact factor: 2.846

3.  miR-211 regulates the antioxidant function of lens epithelial cells affected by age-related cataracts.

Authors:  Bo Lu; Ian T Christensen; Li-Wei Ma; Tao Yu; Ling-Feng Jiang; Chun-Xia Wang; Li Feng; Jin-Song Zhang; Qi-Chang Yan; Xin-Ling Wang
Journal:  Int J Ophthalmol       Date:  2018-03-18       Impact factor: 1.779

4.  miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6.

Authors:  Bairong Xia; Shanshan Yang; Tianbo Liu; Ge Lou
Journal:  Mol Cancer       Date:  2015-03-11       Impact factor: 27.401

5.  MicroRNA-211 promotes non-small-cell lung cancer proliferation and invasion by targeting MxA.

Authors:  Mafei Kang; Jieqiong Shi; Na Peng; Shaozhong He
Journal:  Onco Targets Ther       Date:  2017-11-28       Impact factor: 4.147

6.  Upregulation of miR-211 Promotes Chondrosarcoma Development via Targeting Tumor Suppressor VHL.

Authors:  Changbao Chen; Aixian Tian; Hua Zhou; Xiaolin Zhang; Zhongjun Liu; Xinlong Ma
Journal:  Onco Targets Ther       Date:  2020-04-05       Impact factor: 4.147

7.  Dissecting Molecular Heterogeneity of Circulating Tumor Cells (CTCs) from Metastatic Breast Cancer Patients through Copy Number Aberration (CNA) and Single Nucleotide Variant (SNV) Single Cell Analysis.

Authors:  Tania Rossi; Davide Angeli; Michela Tebaldi; Pietro Fici; Elisabetta Rossi; Andrea Rocca; Michela Palleschi; Roberta Maltoni; Giovanni Martinelli; Francesco Fabbri; Giulia Gallerani
Journal:  Cancers (Basel)       Date:  2022-08-14       Impact factor: 6.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.